CSTL · Castle Biosciences Inc · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| $365M – $375M | $357.28M | $344.23M | $332.07MG | $219.79M | $137.04M | $94.09MG | $62.65M | $51.87M | $22.79M | |
| — | $81.25M | $71.03M | $60.21M | $44.98M | $32.01M | $15.82M | $9.69M | $7.31M | $5.3M | |
| — | $57.72M | — | — | — | — | — | $52.96M | $44.56M | $17.49M | |
| — | — | — | — | — | — | — | 84.54% | 85.91% | 76.75% | |
| — | $55.45M | $51.85M | $52.04M | $53.62M | $44.9M | $29.65M | $13.26M | $7.39M | $4.85M | |
| — | $243.66M | $229.32M | $200.05M | $180.15M | $143M | $86.74M | $48.13M | $29.84M | $16.47M | |
| — | $9.03M | $34.84M | $11.11M | $9.01M | $8.27M | $1.96M | $0 | $4000 | $36K | |
| — | $15.59M | $40.77M | $16M | $12.33M | $10.54M | $3.41M | $472K | — | — | |
| — | — | — | — | — | — | — | — | $37.23M | $21.33M | |
| — | -$32.11M | -$42.81M | $8.67M | -$67.98M | -$72.86M | -$40.08M | -$6.54M | $7.33M | -$3.84M | |
| — | — | -12.44% | 2.61% | -30.93% | -53.16% | -42.6% | -10.44% | 14.13% | -16.83% | |
| — | -$16.52M | -$2.04M | $24.67M | -$55.65M | -$62.31M | -$36.67M | -$6.07M | — | — | |
| — | $375K | $86K | $577K | $11K | $17K | $1000 | $2.63M | $4.57M | $2.27M | |
| — | $10.63M | $11.77M | $12.92M | $10.62M | $3.97M | $68K | $373K | $312K | $24K | |
| — | -$448K | $144K | $0 | $0 | — | — | $0 | -$2.93M | -$272K | |
| — | $212K | -$5.36M | $3.32M | $101K | -$1.77M | -$8.72M | $84K | $72K | $9000 | |
| — | -$19.42M | -$24.16M | $18.25M | -$57.47M | -$67.14M | -$31.29M | -$10.28M | $5.28M | -$6.37M | |
| — | — | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% | -16.42% | 10.17% | -27.94% | |
| — | — | — | — | — | — | — | -$10.28M | $2.99M | -$10.16M | |
| — | -$19.71M | -$24.12M | $18.34M | -$56.95M | -$67.52M | -$31.29M | -$10.28M | $5.28M | -$6.37M | |
| USD/shares | — | -$0.65 | -$0.83 | $0.66 | -$2.14 | -$2.58 | -$1.24 | -$0.54 | $0.35 | -$5.33 |
| USD/shares | — | -$0.64 | -$0.83 | $0.62 | -$2.14 | -$2.58 | -$1.24 | -$0.54 | -$0.21 | -$5.33 |
| shares | — | — | 28.99M | 27.78M | 26.8M | 26.05M | 25.14M | 18.93M | 8.58M | 1.91M |
| shares | — | — | 28.99M | 29.26M | 26.8M | 26.05M | 25.14M | 18.93M | 8.66M | 1.91M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 19 similar-size Diagnostics & Research companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $344,229,000 | $332,069,000 | $219,788,000 | $137,039,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Dermatologic | $216,369,000 | $256,996,000 | $183,375,000 | $124,809,000 | $85,753,000 | $57,646,000 |
| Non-Dermatologic | $127,860,000 | $75,073,000 | $36,413,000 | $12,230,000 | — | — |
| Service Other | — | — | — | — | $8,332,000 | $5,003,000 |